US equities |
SPCX $168.82 ▲+6.20% NVDA $237.50 ▲+1.52% MU $1,065.03 ▼-0.92% TSLA $380.60 ▲+2.70% MSFT $524.70 ▲+1.39% SNDK $1,713.59 ▼-0.37% INTC $116.83 ▼-2.10% META $744.33 ▲+2.23%
FinancialContent

Seer, Inc. - Class A Common Stock (NQ:SEER)

2.320 +0.070 (+3.11%)
Delayed Quote Updated: 1:41 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Seer, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Seer Redefining Deep Unbiased Proteomics with Launch of New Proteograph Workflow at ASMS 2025, Enabling Previously Unattainable Scale and Efficiency
From Seer, Inc.
Via GlobeNewswire
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Seer Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook
Revenue grew 37%, driven by increased product sales and service revenue 
From Seer, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For February 27, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 13, 2025 ↗
 
Via Benzinga
News headline image
Seer to Report First Quarter 2025 Financial Results on May 13, 2025
From Seer, Inc.
Via GlobeNewswire
News headline image
Seer Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Outlook
Validated technology with exceptional growth of customer publications and enhanced access to the Proteograph Product Suite with growing demand for Seer Technology Access Center (STAC) 
From Seer, Inc.
Via GlobeNewswire
News headline image
Seer to Participate in the TD Cowen 45th Annual Health Care Conference
From Seer, Inc.
Via GlobeNewswire
News headline image
Seer to Feature Proteomic Advancements in Cancer and RNA Therapy Research among other Findings at US HUPO 2025
Seminar from Dr. Jinjun Shi from Brigham and Women's Hospital and Harvard Medical School to highlight study of proteomic perturbations resulting from a novel approach to cancer therapy revealed using... 
From Seer, Inc.
Via GlobeNewswire
News headline image
Seer to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
From Seer, Inc.
Via GlobeNewswire
News headline image
Seer to Present at the J.P. Morgan 43rd Annual Healthcare Conference
From Seer, Inc.
Via GlobeNewswire
News headline image
Seer Ranked Number 57 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
Attributes 2,440% revenue growth to increased adoption of its Proteograph™ Product Suite and exciting discoveries made by Seer customers across multiple areas of biology and disease 
From Seer, Inc.
Via GlobeNewswire
News headline image
Seer to Participate in Upcoming November Investor Conferences
From Seer, Inc.
Via GlobeNewswire
News headline image
Seer Reports Third Quarter 2024 Financial Results
Growing enthusiasm for Proteograph Product Suite with multiple larger orders from government agencies and continued strong interest in STAC 
From Seer, Inc.
Via GlobeNewswire
News headline image
Seer Enters into a Co-Marketing and Sales Agreement with Thermo Fisher Scientific
Collaboration enhances unprecedented access to deep, unbiased proteomics at scale, enabling deeper insights into human biology 
From Seer, Inc.
Via GlobeNewswire
News headline image
Seer Highlights Capability of Deep Proteomics to Enhance Genomic Insights Into Alzheimer’s, Lung Cancer, and More at ASHG 2024
CoLab session with PrognomiQ and Salk Institute plus multiple presentations of new data offer firsthand look at multi-omic breakthroughs powered by Seer’s Proteograph™ Product Suite 
From Seer, Inc.
Via GlobeNewswire
News headline image
Seer Showcases Scalable Proteomic Advancements Impacting Alzheimer’s, Population Health, and Xenotransplantation at HUPO 2024
Seer’s Proteograph™ Product Suite reveals new insights into Alzheimer’s pathways, drives population-scale plasma analysis, and captures immune dynamics in xenotransplantation—with additional... 
From Seer, Inc.
Via GlobeNewswire
News headline image
Seer to Report Third Quarter 2024 Financial Results on November 6, 2024
From Seer, Inc.
Via GlobeNewswire
News headline image
Seer to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Seer, Inc.
Via GlobeNewswire
News headline image
Seer Appoints Nicolas Roelofs to its Board of Directors
From Seer, Inc.
Via GlobeNewswire
News headline image
Seer to Participate in the Canaccord Genuity 44th Annual Growth Conference
From Seer, Inc.
Via GlobeNewswire
News headline image
SEER Stock Earnings: Seer Beats EPS, Misses Revenue for Q2 2024 ↗
SEER stock results show that Seer beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Seer Reports Second Quarter 2024 Financial Results
Launched STAC in Europe and additional customer papers published in leading journals 
From Seer, Inc.
Via GlobeNewswire
News headline image
Seer to Report Second Quarter 2024 Financial Results on August 8, 2024
From Seer, Inc.
Via GlobeNewswire
News headline image
Seer Proteograph™ Provides Differentiated Insights into Spaceflight Proteomic Alterations for Precision Medicine and Biomarker Discovery
From Seer, Inc.
Via GlobeNewswire
News headline image
Seer Technology Access Center Provides Unprecedented Scale and Depth of Coverage for PrognomiQ’s Early Cancer Detection Study
Combined Workflow of Proteograph™ XT Assay and Thermo Scientific™ Orbitrap™ Astral™ Mass Spectrometer Robustly Identifies over 13,000 Protein Groups Across a Study of 2,840 Subjects 
From Seer, Inc.
Via GlobeNewswire
News headline image
SEER Stock Earnings: Seer Meets EPS, Misses Revenue for Q1 2024 ↗
SEER stock results show that Seer met analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Seer Reports First Quarter 2024 Financial Results
Demonstrated the power of the Proteograph Product Suite with a growing number of customer presentations and publications 
From Seer, Inc.
Via GlobeNewswire
News headline image
Seer Launches New Technology Access Center in Europe to Expand Accessibility to Unbiased Proteomic Solutions
From Seer, Inc.
Via GlobeNewswire
News headline image
Seer to Report First Quarter 2024 Financial Results on May 8, 2024
From Seer, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >